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Overview
• Identify primary brain regions & describe their central functions
• Describe some of the “normal” neuropsychological changes that 
occur with advancing age
• Develop a broader understanding of most common aging-related 
Neurocognitive Disorders & their characteristic signs / symptoms
• Identify at least one key aspect of each primary type of 
Neurocognitive Disorder through basic neurocognitive screening
• Identify key treatment-, referral-, & continuum-of-care 
considerations / options for those struggling with neurocognitive 
impairment
Note:
Although completion of this workshop will NOT make you 
a qualified neuropsychologist, it WILL give you clinically 
useful information and tools for appropriate neurocognitive 
screening of older adults within the scope of your current 
practice.
Older Adults in South Dakota
• In 2017, approx. 20% of South Dakota residents were ≥ 60 years 
old (≈ 174,000)
• Future Projections (U.S. Census Bureau 2009 estimates):
• 2020 ≈ 22.5% of pop.
• 2030 ≈ 27.5% of pop.
The Central Nervous System
https://www.nlm.nih.gov/medlineplus/ency/imagepages/19588.htm
Neurons
• 50-100 billion throughout CNS (approx. 20 
billion in neocortex alone)
• Most all present at birth
• Can move & grow
• No replication of cells
• Each can receive 100,000 + contacts





• Neural Impulse (Action Potential) = Electrochemical Process
• Action potential expends energy & electromagnetic “fields” 
(glucose, oxygen, blood flow)
Basis of neuroimaging technology (CT, MRI, PET, etc.)
Glial Cells
• Likely >100 billion in neocortex alone        
• Do not transmit information…
• …Instead, implicated in synaptic 
functioning & neural signaling
• Provide
--Structural support
--Nutritional & scavenger functions




• Aging-related decline begins in one’s 20’s-30’s
• Cortical atrophy evident by 40’s
• Decreased Gray Matter Volume:
o Reduced dendrite length / arborization
o Fewer neocortical synapses
• Decreased White Matter Volume
≡ Most signif. overall brain shrinkage








American Psychiatric Association (2013)






Aging & Neurocognitive Domains: General Principles
Lezak, Howieson, Bigler, & Tranel (2012)
• Slowed information processing speed implicated in many “normal” 
cognitive changes
• Education level, etc. influence “brain reserve capacity” & 
cognitive preservation into later years     Cognitive Reserve
• Number of potentially confounding research variables increase 
with advancing subject age…
…So, following data must be discerned carefully (is not 
exhaustive)
A. Learning & Memory
• Long-Term
• Autobiographical
• Semantic (Context-free; general knowledge of symbols & 
concepts + the rules for manipulating them)
• Short-Term
• Verbal—Nonverbal 
• Immediate – Delayed
• Recall – Recognition
A. Learning & Memory - 2
• “Normal” Aging Effects:
• Mild word-finding difficulty (esp. proper names)
• Immediate short-term mem. affected slightly
• Acquisition < retention
• Short-term nonverbal mem. typically more compromised than 
short-term verbal mem.
• Recognition mem. retained well






• “Normal” Aging Effects:
• Simple span intact into 80’s
• Slower responses & more errors on tasks of divided attn.
• Difficulty shifting attn. when given an invalid cue
• Deficits in sustained & selective attn. + distractibility
C. Executive Function
• Abstraction / Reasoning
• Decision-Making
• Mental Flexibility / Planning
• Working Memory
• “Normal” Aging Effects:
• Reasoning w/ familiar material good (yet more concrete)…but 
compromised w/ unfamiliar, complex material
• Abstraction declines (concept formation, too—but in 80’s)










D. Language - 2
• “Normal” Aging Effects:
• Verbal abilities retained well, generally
• Verbal fluency changes (variable research results)





• “Normal” Aging Effects:
• Object- & shape-recognition preserved well
• Visuo-perceptual judgment declines gradually / steadily into
90’s (basic analysis OK, but integration / reasoning decline)
• Diminished accuracy & complexity on some construction tasks
F. Social Cognition
• Emotional Recognition
• Social & Behavioral Propriety
• “Normal” Aging Effects:
• Generally well-preserved
• Declining perceptual abilities may negatively influence 
emotional recognition
Cognitive Aging & Intellectual Ability
Lezak et al. (2012)
• Crystallized Intelligence:
• Over-learned, well-practiced, familiar…
…Skills, ability, & knowledge
• Gains through 60’s, stable through 70’s
• Fluid Intelligence:
• Reasoning & problem-solving for which familiar solutions are 
not available
• Slow decline until late 50’s – early 60’s, then pace of decline 
increases
Neurocognitive Screening: Characteristics
Roebuck-Spencer, Glen, Puente, Denney, Ruff, Hostetter, & Bianchini (2017)
• Narrow in scope
• Minimal administrator training needed
• Brief administration (< 30 min.)
• Provides
o Early identification of those at risk of decline
o Indication of need for referral for additional evaluation / 
treatment
oMeans of monitoring symptom progression or treatment 
response
• Does NOT provide definitive diagnosis
Neurocognitive Screening: Procedures
• Obtain / Review Medical Documentation from PCP, incl.
o Recent, relevant primary care medical notes
oNeuroimaging reports (if avail.)
o Specialist reports (neurology, psychiatry, etc.)
• Thorough, Comprehensive Evaluative Interview
o Interview family / others when possible, also
o The best available strategy you have (likely)!
Neurocognitive Screening: Procedures 
- 2
• Select Screening Instrument(s), e.g.
oMontreal Cognitive Assessment Test (MoCA) 
(www.mocatest.org)
oMini-Mental Status Examination (MMSE)
oGeriatric Depression Scale – Long Form (GDS)
oGeriatric Anxiety Scale (GAS) 
(www.uccs.edu/agingandmentalhealthlab/scale)
Neurocognitive Screening: Procedures 
- 3









Abnormal Cognitive Decline in
Older Adults: The “3 D’s” 
• Differential Diagnosis / Rule-Out’s
• Delirium
• Depression
• Dementia (Major Neurocognitive Disorder)
Delirium: DSM-5 Criteria
A. A disturbance in attention (i.e., reduced ability to direct, focus, sustain, and shift attention) and 
awareness (reduced orientation to the environment).
B. The disturbance develops over a short period of time (usually hours to a few days), represents a 
change from baseline attention and awareness, and tends to fluctuate in severity during the 
course of a day.
C. An additional disturbance in cognition (e.g., memory deficit, disorientation, language, visuo-
spatial ability, or perception). 
D. The disturbances in Criteria A and C are not better explained by another preexisting, established, 
or evolving neurocognitive disorder and do not occur in the context of a severely reduced level of 
arousal, such as coma. 
E. There is evidence from the history, physical examination, or laboratory findings that the 
disturbance is a direct physiological consequence of another medical condition, substance 
intoxication or withdrawal, or exposure to a toxin, or is due to multiple etiologies.
©American Psychiatric Association (2013). All rights reserved.
Delirium: Key Characteristics
 * Acute onset (typically)
 * Clouding or loss of consciousness (usu. unexplained)
 Impaired cognition (incl. memory & language)
 Confused, “out of touch”, disoriented
 Hallucinations (poss.)
 * Course: Hours  days (some forms = weeks months)
 Waxing/waning fairly common
 Typically caused by a medical condition…
Etiology of Delirium
• Encephalopathy due to…
• Urinary tract infection (esp. older adults)
• Dehydration
• Medication reactions: Intolerance, interactions
• Substance-induced (Note specific coding in DSM-5)
• High fever (esp. children)
• Sleep deprivation (excessive)
• Etc.
Treatment & Prevention of Delirium 
• Treatment
• Address precipitating medical problems
• Psychosocial interventions
• Reassurance/comfort, coping strategies, inclusion of pt. in 
treatment decisions (when poss.)
• Prevention
• Utilize proper medical care for illnesses
• Emphasize proper use of, & adherence to, therapeutic drugs
“Dementia”  Neurocognitive Disorder
• DSM-IV: “Dementia” & “Organic Mental Disorder”                       
 DSM-5: “Neurocognitive Disorder”
• Memory impairment no longer essential for diagnosis
• Includes range of disorders in which principal manifestation is 
an acquired loss of cognitive ability (objective decline from 
baseline) due to known (or assumed) brain damage or disease
“Dementia”  Neurocognitive Disorder
- 2
• All age groups*
• Greater specification of behavioral symptoms / syndromes
• Active use of objective neurocognitive assessment data
• Increasing role of biomarkers in diagnosis (but not yet required)
Neurocognitive Disorder
• Mild
• Cognitive Deficits approx. 1-2 SD’s  below mean on 
neuropsychological testing
• Cognitive deficits do not interfere w/ capacity for independence 
in daily activities
• Major
• Cognitive Deficits > 2 SD’s below mean on neuropsych. testing
• Cog. deficits interfere w/ independence in daily activities
Neurocognitive Disorder: Specifiers
• Differentiation must be made between “possible” & “probable”
• Medical disease / problem that is causing the disorder must be 
specified…
Types (Sources) of Neurocognitive Disorder
• Due to Alzheimer's Disease*
• Frontotemporal
• Vascular*
• With Lewy bodies*
• Due to Traumatic Brain Injury
• Substance/medication 
induced
• Due to HIV infection
• Due to prion disease
• Due to Parkinson’s Disease
• Due to Huntington’s Disease
• Due to another medical 
condition
• Due to multiple etiologies
• Unspecified
Subjective Cognitive Decline (SCD)
• Older adults express concern about perceived decline in cognitive 
abilities—yet, assessment WNL + IADL’s remain intact (Jessen et al., 
2014)
• “Worried well”? (Tuokko & Smart, 2018) or “CRS”?
oNot necessarily—Seems distinct
• SCD  Increased risk of AD when relevant biomarkers present







PET Amyloid & Tau Imaging
Sperling, Mormino, & Johnson (2014)
Slide used by gracious permission of principal author.
Alzheimer’s Disease (AD)
• Most common form of Major Neurocog. Disorder
• Identified by Dr. Alois Alzheimer in 1906 (Auguste D.)
• Char. by progressive brain deterioration & impaired cognitive 
function (esp. memory)






• Plaques (Senile…): Clusters of amyloid beta 42 
oAβ₄₂ very sticky  easily forms plaques among axon terminals
o Interferes w/ neural transmission  Eventual neuron death
• Neurofibrillary Tangles: Abnormal accumulations of tau
o Tangles form inside of neurons  Neuron death
Image: https://www.alz.org/braintour/plaques_tangles.asp
Image: https://www.alz.org/braintour/healthy_vs_alzheimers.asp
Heredity & Alzheimer’s Disease
• A key aspect of AD (accounts for just > 50% of cases)
• Four Known Genes (& associated chromosome):
oAPP (21)
o Presenilin 1 (14)
o Presenilin 2 (1)
oAPOE ε4 (19)   Interacts w/ tau to exacerbate pathogenic 
cascade (Shi et al., 2017)
• Early-Onset AD: Related to APP, Presenilin 1, & APOE-ε4 genes
• Late-Onset AD: Related to Presenilin 2 gene
Detecting / Diagnosing AD
• Autopsy: Most Common / Definitive
• PET Scan
• Comprehensive Medical Evaluation (a rule-out process)
• Neuropsychological Evaluation / Neurocognitive Screening:
o Look for insidious onset & gradual progression
oAnosognosia common ( Denial)
o Short-term verbal memory impairment often primary symptom
oWord-finding problems common
Current Alzheimer’s Medication 
Options
• Acetylcholinesterase Inhibitors
• A.k.a. Aricept, Razadyne, Exelon
• Inhibits acetylcholinesterase from breaking down ACh, thereby 
preserving neuronal transmission
• Effectively slows progression of AD—but does not stop it
Current Alzheimer’s Medication 
Options - 2
• NMDA [N-methyl-D-aspartate] Blockers
• A.k.a. Namenda
• Limits NMDA receptor sensitivity to glutamate
• Mechanism: Some dying AD neurons trigger release of 
glutamate  excitotoxicity (overstimulation of NMDA 
receptors)  neuron death
• Also FDA indicated for Neurocog. Disorder w/ Lewy Bodies 
(DLB)
Vascular Neurocognitive Disorder
• Second most common form of Neurocog. Disorder
• Cause:
• Damage to, or deterioration of, the vascular integrity of brain
• Sources:
• Cerebrovascular disease, cardiac disease, hypertension, high 
cholesterol, smoking, etc.
• Variable pattern of neurocognitive impairment
Vascular Neurocognitive Disorder - 2
• “Probable” if (≥ 1 of following)…
• Clinical criteria supported by neuroimaging evidence of signif. 
lesions, attributed to cerebrovascular disease
• Neurocog. syndrome is temporally related to ≥ 1 documented 
cerebrovascular events
• Clinical & genetic evidence of cerebrovascular disease is 
present
Stroke: Primary Types 
• Ischaemic
• Arterial clogging / blockage
• TIA if < 24 hrs. (usu. w/ symptom remission),                        
CVA / Stroke if > 24 hrs.
• Hemorrhagic





Subcortical Ischaemic Vascular Disease
Image: http://ischemicskolik.blogspot.com/2015/08/chronic-ischemic-changes-in-brain.html
Detecting / Diagnosing Vascular 
Neurocognitive Disorder
• Documented Evidence of Cerebrovascular Disease
• Stepwise progression of cognitive impairment common
• Neuropsychological Evaluation / Neurocognitive Screening:
o Look for temporal causation
o Look for correlation between lesion location(s) & affected 
cognitive function
oClient often (not always) aware of problems
Neurocognitive Disorder w/ Lewy Bodies
• Third most common form of Neurocog. Disorder
oA.k.a. DLB or Lewy Body Disease
• Apparent Hybrid: Symptoms / characteristics of Parkinson’s 
Disease & Alzheimer’s Disease…
• Episodes of seemingly unexplained clouding or loss of 
consciousness
• Episodes of seemingly unexplained falling
Neurocognitive Disorder w/ Lewy Bodies  
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• Apparent Hybrid [cont.] ….
• Spontaneous development of “parkinsonism” (tremors, etc.) 
after dev’t of cognitive problems (often starting w/ executive 
dysfunction)
• Recurrent visual hallucinations (well-formed, detailed)
• Severe neuroleptic sensitivity
• REM Sleep Behavior Disorder criteria met
Lewy Bodies
• Abnormal protein accumulation inside neurons
• Found in pts w/ Parkinson's disease (PD), Lewy Body Disease 
(Neurocognitive Disorder due to…), & a few others





Detecting / Diagnosing Neurocognitive 
Disorder w/ Lewy Bodies
• Documented Evidence of Clouding / Loss of Consciousness and / 
or Unexplained Falling
• Histologic Evidence of Lewy Bodies
• Neuropsychological Evaluation / Neurocognitive Screening:
o Look for relatively intact short-term memory functioning early
o Executive dysfunction often an early issue
oDo cognitive problems precede Parkinsonism?
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